GASTROESOPHAGEAL-JUNCTION CANCER

This study tests a new combination of drugs (iparomlimab and tuvonralimab, called QL1706) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if the combo can shrink tumors and control the disease…

This phase 3 trial tests whether a newer targeted drug (Enhertu) combined with chemotherapy and an immunotherapy (pembrolizumab) works better than the current standard treatment for advanced HER2-positive stomach or gastroesophageal junction cancer. About 726 adults who have not …

This study tests whether adding a new experimental drug (HLX22) to the standard two-drug treatment can help people with advanced HER2-positive stomach or gastroesophageal cancer live longer without their cancer growing. About 550 adults who have not had prior treatment for their …

This early-stage trial tests a new drug (CA-4948) combined with standard chemotherapy and immunotherapy for people with untreated stomach or esophageal cancer that cannot be removed by surgery. The study includes two groups: one for HER2-negative cancer and one for HER2-positive …

This study tests whether combining the immunotherapy drug adebrelimab with other targeted drugs and chemotherapy can help shrink tumors in people with stomach or gastroesophageal junction cancer. About 200 adults who have not had prior treatment for their cancer will receive one …

This study tests a new drug, AZD0901, against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has not responded to prior therapy. The trial includes 572 adults whose tumors have a specific marker called CLDN18.2. The main goals are to…

This study compares two surgeries—proximal gastrectomy and total gastrectomy—for people with locally advanced gastroesophageal junction cancer. About 120 adults aged 18 to 90 will be randomly assigned to one surgery type. The goal is to see which approach leads to better 3-year c…

This early-phase study tests a new drug called AZD4360 in adults with advanced stomach, bile duct, or pancreatic cancers that have not responded to prior treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 117 participa…

This early-phase study tests a new drug called BL-M07D1 in adults with advanced HER2-positive solid tumors (including breast, lung, stomach, and ovarian cancers) that have not responded to at least two prior treatments. The main goals are to check the drug's safety, find the best…

This study tests a new drug called AZD0901, alone or with other cancer drugs, in people with advanced solid tumors that have a specific marker (CLDN18.2). The goal is to see if it is safe and shrinks tumors. About 224 adults with stomach, bile duct, or pancreatic cancer will take…

This study tests a new medicine (PF-08634404) combined with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new combo t…

This early-phase study is testing an experimental drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 …

This early-stage trial tests a new drug called IKS014 in people with advanced HER2-positive breast, stomach, or gastroesophageal cancers that have not responded to other treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells that have high leve…